Jump to content

Anticholinergic

From Wikipedia, the free encyclopedia

Anticholinergics(anticholinergic agents) are substances that block the action of theacetylcholine(ACh)neurotransmitteratsynapsesin thecentralandperipheral nervous system.[1][2]

These agents inhibit theparasympathetic nervous systemby selectively blocking the binding of ACh to its receptor innerve cells.Thenerve fibersof the parasympathetic system are responsible for the involuntary movement ofsmooth musclespresent in thegastrointestinal tract,urinary tract,lungs,sweat glands,and many other parts of the body.[3]

In broad terms, anticholinergics are divided into two categories in accordance with their specific targets in the central and peripheral nervous system and at the neuromuscular junction:[3]antimuscarinicagents andantinicotinicagents (ganglionic blockers,neuromuscular blockers).[4]

The term "anticholinergic" is typically used to refer to antimuscarinics which competitively inhibit the binding of ACh tomuscarinic acetylcholine receptors;such agents do not antagonize the binding atnicotinic acetylcholine receptorsat theneuromuscular junction,although the term is sometimes used to refer to agents which do so.[3][5]

Medical uses[edit]

Anticholinergic drugs are used to treat a variety of conditions:

Anticholinergics generally haveantisialagogueeffects (decreasing saliva production), and most produce some level of sedation, both being advantageous in surgical procedures.[8][9]

Until the beginning of the 20th century, anticholinergic drugs were widely used to treat psychiatric disorders.[10]

Physiological effects[edit]

Effects of anticholinergic drugs include:

Clinically the most significant feature isdelirium,particularly in the elderly, who are most likely to be affected by thetoxidrome.[3]

Side effects[edit]

Long-term use may increase the risk of both cognitive and physical decline.[14][15]It is unclear whether they affect the risk of death generally.[14]However, in older adults they do appear to increase the risk of death.[16]

Possible effects of anticholinergics include:

Possible effects in thecentral nervous systemresemble those associated withdelirium,and may include:

  • Confusion
  • Disorientation
  • Agitation
  • Euphoriaordysphoria
  • Respiratory depression
  • Memory problems[19]
  • Inability to concentrate
  • Wandering thoughts; inability to sustain atrain of thought
  • Incoherent speech
  • Irritability
  • Mental confusion (brain fog)
  • Wakefulmyoclonic jerking
  • Unusual sensitivity to sudden sounds
  • Illogical thinking
  • Photophobia
  • Visual disturbances[citation needed]
    • Periodic flashes of light
    • Periodic changes in visual field
    • Visual snow
    • Restricted or "tunnel vision"
  • Visual, auditory, or other sensoryhallucinations
    • Warping or waving of surfaces and edges
    • Textured surfaces
    • "Dancing" lines; "spiders", insects;form constants
    • Lifelike objects indistinguishable from reality
    • Phantom smoking
    • Hallucinated presence of people not actually there (e.g.shadow people)
  • Rarely: seizures, coma, and death
  • Orthostatic hypotension(severe drop in systolic blood pressure when standing up suddenly) and significantly increased risk of falls in the elderly population[20]

Older patients are at a higher risk of experiencing CNS side effects.[citation needed]The link possible between anticholinergic medication use and cognitive decline/dementia has been noted in weaker observational studies.[21]Although there is no strong evidence from randomized controlled trials to suggest that these medications should be avoided, clinical guidelines suggest that a consideration be made to decrease the use of these medications if safe to do so and the use of these medications be carefully considered to reduce any possible adverse effects including cognitive decline.[21]

Toxicity[edit]

An acute anticholinergic syndrome is reversible and subsides once all of the causative agents have been excreted. Reversibleacetylcholinesterase inhibitoragents such asphysostigminecan be used as an antidote in life-threatening cases. Wider use is discouraged due to the significant side effects related to cholinergic excess including seizures, muscle weakness, bradycardia, bronchoconstriction, lacrimation, salivation, bronchorrhea, vomiting, and diarrhea. Even in documented cases of anticholinergic toxicity, seizures have been reported after the rapid administration of physostigmine. Asystole has occurred after physostigmine administration for tricyclic antidepressant overdose, so a conduction delay (QRS > 0.10 second) or suggestion of tricyclic antidepressant ingestion is generally considered a contraindication to physostigmine administration.[22]

Pharmacology[edit]

Anticholinergics are classified according to the receptors that are affected:

Examples[edit]

Examples of common anticholinergics:

Antidotes[edit]

Physostigmineis one of only a few drugs that can be used as an antidote for anticholinergic poisoning.Nicotinealso counteracts anticholinergics by activatingnicotinic acetylcholine receptors.Caffeine(although anadenosinereceptor antagonist) can counteract the anticholinergic symptoms by reducing sedation and increasing acetylcholine activity, thereby causing alertness and arousal.

Psychoactive uses[edit]

When a significant amount of an anticholinergic is taken into the body, atoxic reactionknown as acute anticholinergic syndrome may result. This may happen accidentally or intentionally as a consequence of eitherrecreationalorentheogenicdrug use, though many users find the side effects to be exceedingly unpleasant and not worth the recreational effects they experience. In the context of recreational use, anticholinergics are often calleddeliriants.[24]

Plant sources[edit]

The most common plants containing anticholinergicalkaloids(includingatropine,scopolamine,andhyoscyamineamong others) are:

Use as a deterrent[edit]

Several narcotic andopiate-containing drug preparations, such as those containinghydrocodoneandcodeineare combined with an anticholinergic agent to deter intentional misuse.[32]Examples includehydrocodone/homatropine(Tussigon, Hydromet, Hycodan),diphenoxylate/atropine(Lomotil), andhydrocodone polistirex/chlorpheniramine polistirex(Tussionex Pennkinetic, TussiCaps). However, it is noted that opioid/antihistamine combinations are used clinically for their synergistic effect in the management of pain and maintenance of dissociativeanesthesia(sedation) in such preparations asmeperidine/promethazine(Mepergan) anddipipanone/cyclizine(Diconal), which act as strong anticholinergic agents.[33]

References[edit]

  1. ^"Anticholinergics",Anticholinergic Agents,Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases, 2012,PMID31643610,retrieved2020-03-23,Anticholinergics have antisecretory activities and decrease nasal and bronchial secretions, salivation, lacrimation, sweating and gastric acid production, and can be used to decrease secretions in allergic and inflammatory diseases. Anticholinergics relax smooth muscle in the gastrointestinal tract, bladder and lung and can be used for gastrointestinal, urological or respiratory conditions associated with spasm and dysmotility.
  2. ^Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2009. Drugs with Anticholinergic Activity. Prescriber's Letter 2011; 18 (12):271233.
  3. ^abcdeMigirov, A; Datta, AR (2020), "article-17683",Physiology, Anticholinergic Reaction,This book is distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, a link is provided to the Creative Commons license, and any changes made are indicated., Treasure Island (FL): StatPearls Publishing,PMID31536197,retrieved2020-03-24
  4. ^Sharee A. Wiggins; Tomas Griebling."Urinary Incontinence".Landon Center on Aging. Archived fromthe originalon 2011-09-27.Retrieved2011-07-09.
  5. ^Su, Mark; Goldman, Matthew. Traub, Stephen J.; Burns, Michele M.; Grayzel, Jonathan (eds.)."Anticholinergic poisoning".UpToDate.Retrieved2020-03-24.
  6. ^"NERVE AGENTS".fas.org.Retrieved2020-07-27.
  7. ^Nair, V. Priya; Hunter, Jennifer M. (2004-10-01)."Anticholinesterases and anticholinergic drugs".Continuing Education in Anaesthesia, Critical Care & Pain.4(5): 164–168.doi:10.1093/bjaceaccp/mkh045.ISSN1743-1816.
  8. ^Page 592 in:Cahalan, Michael D.; Barash, Paul G.; Cullen, Bruce F.; Stoelting, Robert K. (2009).Clinical Anesthesia.Hagerstwon, MD: Lippincott Williams & Wilkins.ISBN978-0-7817-8763-5.
  9. ^Barash, Paul G. (2009).Clinical Anesthesia.Lippincott Williams & Wilkins.ISBN9780781787635.Archivedfrom the original on 20 February 2017.Retrieved8 December2014.
  10. ^Bangen, Hans:Geschichte der medikamentösen Therapie der Schizophrenie.Berlin 1992,ISBN3-927408-82-4
  11. ^"ATROPINE- atropine sulfate solution/ drops".DailyMed.2017-11-20.Retrieved2020-03-28.
  12. ^"MYDRIACYL- tropicamide solution/ drops".DailyMed.2019-12-13.Retrieved2020-03-28.
  13. ^"MYDRIACYL- tropicamide solution/ drops".DailyMed.2019-12-13.Retrieved2020-03-28.
  14. ^abFox, C; Smith, T; Maidment, I; Chan, WY; Bua, N; Myint, PK; Boustani, M; Kwok, CS; Glover, M; Koopmans, I; Campbell, N (September 2014)."Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review".Age and Ageing.43(5): 604–15.doi:10.1093/ageing/afu096.PMID25038833.
  15. ^Andre, L; Gallini, A; Montastruc, F; Montastruc, JL; Piau, A; Lapeyre-Mestre, M; Gardette, V (29 August 2019). "Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: a systematic review".European Journal of Clinical Pharmacology.75(12): 1631–1644.doi:10.1007/s00228-019-02744-8.PMID31468067.S2CID201675824.
  16. ^Ruxton, K; Woodman, RJ; Mangoni, AA (2 March 2015)."Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: A systematic review and meta-analysis".British Journal of Clinical Pharmacology.80(2): 209–20.doi:10.1111/bcp.12617.PMC4541969.PMID25735839.
  17. ^Falk, N; Cole, A; Meredith, TJ (15 March 2018). "Evaluation of Suspected Dementia".American Family Physician.97(6): 398–405.PMID29671539.
  18. ^Gray SL, Anderson ML, Dublin S, Hanlon JT,Hubbard R,Walker R, et al. (March 2015)."Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study".JAMA Internal Medicine.175(3): 401–407.doi:10.1001/jamainternmed.2014.7663.PMC4358759.PMID25621434.
  19. ^Talan, Jamie (July–August 2008)."Common Drugs May Cause Cognitive Problems".Neurology Now.4(4): 10–11.doi:10.1097/01.NNN.0000333835.93556.d1.Archived fromthe originalon 2019-06-26.Retrieved26 June2019.
  20. ^"Lifeline Learning Center".Lifeline.theonlinelearningcenter. Archived fromthe originalon 12 July 2012.Retrieved8 December2014.
  21. ^abTaylor-Rowan, Martin; Alharthi, Ahmed A.; Noel-Storr, Anna H.; Myint, Phyo K.; Stewart, Carrie; McCleery, Jenny; Quinn, Terry J. (2023-12-08). "Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment".The Cochrane Database of Systematic Reviews.2023(12): CD015405.doi:10.1002/14651858.CD015405.pub2.ISSN1469-493X.PMC10704558.PMID38063254.
  22. ^Rosen, Peter, John A. Marx, Robert S. Hockberger, and Ron M. Walls. Rosen's Emergency Medicine: Concepts and Clinical Practice. 8th ed. Philadelphia, PA: Mosby Elsevier, 2014.
  23. ^abcde"[113] How well do you know your anticholinergic (antimuscarinic) drugs? | Therapeutics Initiative".Therapeutics Initiative.10 September 2018.Retrieved20 September2018.
  24. ^abBersani, F. S.; Corazza, O.; Simonato, P.; Mylokosta, A.; Levari, E.; Lovaste, R.; Schifano, F. (2013). "Drops of madness? Recreational misuse of tropicamide collyrium; early warning alerts from Russia and Italy".General Hospital Psychiatry.35(5): 571–3.doi:10.1016/j.genhosppsych.2013.04.013.PMID23706777.
  25. ^Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). "Bupropion and Bupropion Analogs as Treatments for CNS Disorders".Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse.Advances in Pharmacology. Vol. 69. pp. 177–216.doi:10.1016/B978-0-12-420118-7.00005-6.ISBN9780124201187.PMID24484978.
  26. ^Dwoskin, Linda P. (29 January 2014).Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse.Elsevier Science. pp. 177–216.ISBN978-0-12-420177-4.Archivedfrom the original on 20 March 2017.
  27. ^Tasman, Allan; Kay, Jerald; Lieberman, Jeffrey A.; First, Michael B.; Maj, Mario (11 October 2011).Psychiatry.John Wiley & Sons.ISBN978-1-119-96540-4.Archivedfrom the original on 20 March 2017.
  28. ^Damaj, M. I.; Flood, P; Ho, K. K.; May, E. L.; Martin, B. R. (2004). "Effect of Dextrometorphan and Dextrorphan on Nicotine and Neuronal Nicotinic Receptors: In Vitro and in Vivo Selectivity".Journal of Pharmacology and Experimental Therapeutics.312(2): 780–5.doi:10.1124/jpet.104.075093.PMID15356218.S2CID149958.
  29. ^Lee, Jun-Ho; Shin, Eun-Joo; Jeong, Sang Min; Kim, Jong-Hoon; Lee, Byung-Hwan; Yoon, In-Soo; Lee, Joon-Hee; Choi, Sun-Hye; Lee, Sang-Mok; Lee, Phil Ho; Kim, Hyoung-Chun; Nah, Seung-Yeol (2006). "Effects of dextrorotatory morphinans on α3β4 nicotinic acetylcholine receptors expressed in Xenopus oocytes".European Journal of Pharmacology.536(1–2): 85–92.doi:10.1016/j.ejphar.2006.02.034.PMID16563374.
  30. ^Hernandez, S. C.; Bertolino, M; Xiao, Y; Pringle, K. E.; Caruso, F. S.; Kellar, K. J. (2000)."Dextromethorphan and Its Metabolite Dextrorphan Block α3β4 Neuronal Nicotinic Receptors".The Journal of Pharmacology and Experimental Therapeutics.293(3): 962–7.PMID10869398.
  31. ^Shytle, RD; Penny, E; Silver, AA; Goldman, J; Sanberg, PR (Jul 2002)."Mecamylamine (Inversine): an old antihypertensive with new research directions".Journal of Human Hypertension.16(7): 453–7.doi:10.1038/sj.jhh.1001416.PMID12080428.
  32. ^"NIH DailyMed – Hydromet Syrup".Dailymed.nlm.nih.gov.Archivedfrom the original on 2011-05-23.Retrieved2008-08-17.
  33. ^Zacny, James P. (2003). "Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers".Psychopharmacology.165(2): 146–156.doi:10.1007/s00213-002-1245-5.PMID12404072.S2CID7835794.